Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

• MAIN FINDING: The first-in-class cdk4/6 inhibitor, PF-06873600, shows promising results when combined with endocrine therapy.
• KEY EVIDENCE: The recommended dose for expansion (RDE) was determined to be 25 mg twice daily based on patient responses.
• APPROACH: The study involved patients with various types of breast cancer, including hormone receptor-positive and triple negative breast cancer.
• SIGNIFICANCE: This research may lead to improved treatment strategies for patients with metastatic breast cancer, enhancing therapeutic options.